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Abstract
Background: Increased postprandial lipid (PPL) response to dietary fat intake is a heritable risk factor for cardiovascular
disease (CVD). Variability in postprandial lipids results from the complex interplay of dietary and genetic factors. We
hypothesized that detailed lipid profiles (eg, sterols and fatty acids) may help elucidate specific genetic and dietary
pathways contributing to the PPL response.
Methods and Results: We used gas chromatography mass spectrometry to quantify the change in plasma concentration of
35 fatty acids and 11 sterols between fasting and 3.5 hours after the consumption of a high-fat meal (PPL challenge) among
40 participants from the GOLDN study. Correlations between sterols, fatty acids and clinical measures were calculated.
Mixed linear regression was used to evaluate associations between lipidomic profiles and genomic markers including single
nucleotide polymorphisms (SNPs) and methylation markers derived from the Affymetrix 6.0 array and the Illumina
Methyl450 array, respectively. After the PPL challenge, fatty acids increased as well as sterols associated with cholesterol
absorption, while sterols associated with cholesterol synthesis decreased. PPL saturated fatty acids strongly correlated with
triglycerides, very low-density lipoprotein, and chylomicrons. Two SNPs (rs12247017 and rs12240292) in the sorbin and SH3
domain containing 1 (SORBS1) gene were associated with b-Sitosterol after correction for multiple testing (P#4.5*10210).
SORBS1 has been linked to obesity and insulin signaling. No other markers reached the genome-wide significance threshold,
yet several other biologically relevant loci are highlighted (eg, PRIC285, a co-activator of PPARa).
Conclusions: Integration of lipidomic and genomic data has the potential to identify new biomarkers of CVD risk.
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Introduction
Hypertriglyceridemia and mixed dyslipidemia (i.e., high levels
of low-density lipoprotein cholesterol (LDL-C) and triglycerides
(TG) combined with decreased levels of high-density lipoprotein
cholesterol (HDL-C)) are important in the development and
progression of atherosclerosis [1]. Most clinical lipid measures
continue to be assessed in the fasting state despite the fact that
humans spend a considerable amount of time in a non-fasting,
postprandial state and experience continuous fluctuations in the
degree of lipemia throughout the day [2]. Large population-based
studies have shown that delayed elimination of postprandial lipids
increases cardiovascular disease (CVD) risk [3,4,5]. For example,
the Copenhagen City Heart Study reported increasing levels of
non-fasting cholesterol and non-fasting TGs were similarly
associated with increasing risk of myocardial infarction over 31
years of follow-up, with non-fasting TGs being the strongest
predictor in women and non-fasting cholesterol the strongest
predictor in men [6].
An increased postprandial lipid (PPL) response may be inherited
[7,8]. In one report, postprandial TG levels were compared in
healthy sons of men with angiographic evidence of severe coronary
heart disease (CHD) versus sons of control subjects without CHD
after the consumption of a high-fat liquid drink [7]. Results
showed fasting lipids were comparable between groups, but the
sons of men with CHD had significantly higher plasma TG levels
after 8, 10, and 12 hours postprandially, suggesting delayed
clearance. Additionally, our own work in GOLDN estimated the
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slope of TG increase 3.5 hours after a postprandial intervention
had close to 80% heritability. Despite promising hypotheses (e.g.,
remnant triglyceride rich lipoproteins cause endothelial dysfunc-
tion), the pathogenesis of a prolonged postprandial response
remains incompletely understood [2,9]. A deeper understanding of
the environmental and genetic factors influencing the PPL
response will be important in developing behavioral and
pharmacologic approaches to CVD prevention and treatment.
To date, studies seeking to identify genetic predictors of the PPL
response in free-living populations can claim qualified success. A
number of studies have documented that variants in genes such as
APOA1, A2, A4, A5, E, C1, C3; LPL; LIPC; SCARB1; MTP, GCKR;
and those encoding fatty acid binding and transport proteins,
explain some of the inter-individual variability [2,10,11]. Despite
progress, current findings do not fully explain the heritable
component of the PPL response. The lipidome, as a subset of the
metabolome, may offer more precise postprandial phenotypes
than clinically measured lipid species. Previous studies have
suggested lipidomic profiles are both heritable and under strong
genetic control [12,13]. We hypothesize that a controlled diet
intervention enriched for saturated fat and cholesterol will allow
more precise assessment of lipidomic postprandial changes [14]
and will facilitate genetic and epigenetic discovery. The current
study measured sterols and total fatty acid content across lipid
classes in human plasma after a PPL intervention as part of the
Genetics of Lipid-lowering Drugs and Diet Network Study
(GOLDN). Genome-wide association study (GWAS) data and
epigenome-wide association study (EWAS) data assayed using the
Affymetrix 6.0 and the Illumina Methyl450 array, respectively,
were associated with newly captured phenotypes before and after
the high fat meal. Previous studies have identified correlations
between genetic variation and the quantitative trait of DNA
methylation enriched at nearby loci (cis-meQTLs) [15]. To
interpret the potential for functional crosstalk between DNA
sequence variants and methylation marks, we also examined cis-




The study protocol was approved by the Institutional Review
Boards at the University of Minnesota, University of Utah, Tufts
University/New England Medical Center, and the University of
Alabama at Birmingham. Written informed consent was obtained
from all participants.
Study population
The GOLDN study was designed to identify genes that
determine response of lipids to two interventions, one to raise
(ingestion of high-fat meal) and one to lower lipid levels
(fenofibrate treatment) [16] (registered at clinicaltrails.gov,
number NCT00083369; URL, http://clinicaltrials.gov/ct2/
show/NCT00083369). The GOLDN study has been previously
described in Irvin et al. [17]. Briefly, the study ascertained and
recruited families from the Family Heart Study at two centers,
Minneapolis, MN and Salt Lake City, UT, who were self-reported
to be white. In each case, only families with at least two siblings
were recruited and only participants who did not take lipid-
lowering agents (pharmaceuticals or nutraceuticals) for at least 4
weeks prior to the initial visit were included. A total of 1048
GOLDN participants were included in the diet intervention. For
the current study, sterols and fatty acids were measured from
stored plasma (280 degrees Celsius) collected at fasting and
3.5 hours after the diet intervention (described below) for 40
GOLDN participants from 24 independent families, for whom
EWAS data and GWAS data were available. The 3.5 hour time
point was chosen for this study as it maximized the postprandial
differences observed between individuals in our data facilitating
genomic discovery. The phenotype and genotype data relevant to
this study was deposited in The database of Genotypes and
Phenotypes (dbGaP) with accession number phs000741.v1.p1.
Postprandial intervention and clinical measurements
For the GOLDN diet intervention, participants were asked to
fast for $12 hours and abstain from alcohol intake for $24 hours
before visiting the clinic. The PPL intervention followed the
protocol of Patsch et al. [18]. The whipping cream/dry milk meal
had 700 calories/m2 body surface area (2.93 MJ/m2 body surface
area): 3% of calories were derived from protein (instant nonfat dry
milk), 14% from carbohydrate (sugar), and 83% from fat sources
(heavy whipping cream). The ratio of polyunsaturated to saturated
fat was 0.06 and the cholesterol content of the average meal was
240 mg. The mixture was blended with ice and 15 mL of
chocolate- or strawberry-flavored syrup to increase the palatabil-
ity. Blood samples were drawn immediately before (fasting) and at
3.5 and 6 hours after consuming the high-fat meal. At each of the
three time points TGs were measured by glycerol-blanked
enzymatic method. Cholesterol was measured using a cholesterol
esterase–cholesterol oxidase reaction. The same reaction was also
used to measure HDL-C after precipitation of non-HDL-C with
magnesium/dextran. LDL-C was measured by a homogeneous
direct method. We also used nuclear magnetic resonance (NMR)
spectroscopy to measure very low-density lipoprotein cholesterol
(VLDL-C) and chylomicrons. TGs, HDL-C, LDL-C, VLDL-C,
chylomicrons and total cholesterol as described are referred to as
clinical lipids in the context of this study. The remaining clinical
measures were captured only once at fasting (or baseline) and
include high-sensitivity C-reactive protein (hsCRP) measured on
the Hitachi 911 using a latex particle enhanced immunoturbidi-
metric assay (Kamiya Biomedical Company, Seattle, WA, USA).
Interleukin-6 (IL6), IL-2 soluble receptor (IL2sR)-a, tumor
necrosis factor (TNF)-a, and monocyte chemoattractant protein-
1 (MCP1) were measured using quantitative sandwich enzyme
immunoassay techniques (ELISA kit assays, R&D Systems Inc.,
Minneapolis, MN, USA) as described in previous publications
[19,20]. Plasma adiponectin and insulin were measured by a
commercial kit using competitive RIA (Linco Research, St
Charles, MO, USA). Plasma glucose was determined by a
hexokinase-mediated reaction on the Hitachi commercial kit
(Roche Diagnostics). We measured weight with a beam balance,
hip circumference at maximal hip girth, and waist circumference
at the umbilicus. Body mass index (BMI) was calculated as weight
(kg)/height (m)2.
TrueMass sterol panel
Deuterium-labeled internal standards were added to 25 mL of
stored plasma from blood drawn at 0 and 3.5 hours and the
mixture was saponified in ethanolic KOH. Free sterols were
extracted in hexane:ethanol, dried under nitrogen, and derivatized
with Tri-Sil in decane. The silated free sterols were injected onto a
6890/5975 GC/MS (Agilent Technologies, CA) with a DB-5MS
UI column (Agilent Technologies, CA) with helium as the carrier.
Mass spectroscopic analysis was performed in the single ion
monitoring (SIM) mode with electron ionization. Prior to each
assay the instruments were calibrated including analysis of
reference standards. Quality control (QC) samples were included
with each batch to continuously monitor the accuracy of the
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platform with time. The absolute concentration of each sterol was
determined by comparing the peak to that of the relevant internal
standard. A total of 11 sterols were quantified in nmols/gram of
sample including total cholesterol, 7-dehydrocholesterol, desmos-
terol, lanosterol, lathasterol, cholestanol, coprostanol, b-sitosterol,
campesterol, stigmasterol, and 7a-hydroxycholesterol (Lipomics,
West Sacramento, CA).
TrueMass fatty acid panel
Lipids were extracted from 25 mL of stored plasma from blood
drawn at 0 3.5 hours in the presence of authentic internal
standards by the method of Folch et al. [21]. The total lipid extract
was trans-esterified in sulfuric acid/methanol to create fatty acid
methyl esters (FAME). The FAME were extracted into hexane and
prepared for gas chromatography. Individual fatty acids were
separated and quantified by capillary gas chromatography (Agilent
Technologies model 6890) equipped with a 30 m HP-88 capillary
column (Agilent Technologies) and a flame-ionization detector.
Instruments were calibrated and QC samples were included in
each batch to continuously monitor the accuracy of the platform
with time. The absolute concentration of each fatty acid in the
original sample was determined by comparing the peak area to
that of the internal standard. A total of 35 fatty acids were
quantified in nmols/gram of sample inlcuding myristic acid (14:0);
pentadecanoic acid (15:0); palmitic (16:0) acid; stearic acid (18:0);
arachidic acid (20:0); behenic acid (22:0); lignoceric acid (24:0);
myristoleic acid (14:1n5); palmitoleic acid (16:1n7); palmitelaidic
acid (t16:1n7); oleic acid (18:1n9); elaidic acid (t18:1n9); vaccenic
acid (18:1n7); linoleic acid (18:2n6); g-linolenic acid (18:3n6); a-
linolenic acid (18:3n3); stearidonic acid (18:4n3); eicosenoic acid
(20:1n9); eicosadienoic acid (20:2n6); mead acid (20:3n9); di-
homo-g-linolenic acid (20:3n6); arachidonic acid (20:4n6); eicsoa-
tetraenoic acid (20:4n3); eicosapentaenoic acid (20:5n3); erucic
acid (22:1n9); docosadienoic acid (22:2n6); adrenic acid (22:4n6);
docosapentaenoic acid (22:5n6); docosapentaenoic acid (22:5n3);
docosahexaenoic acid (22:6n3); nervonic acid (24:1n9); and
plasmalogen derivatives of 16:0, 18:0, 18:1n9, and 18:1n7
(Lipomics, West Sacramento, CA).
Genotyping
DNA extraction and purification in the GOLDN study using
commercial Puregene reagents (Gentra System, Inc, Minneapolis,
MN), following the manufacturer’s instructions has been described
in Irvin et al. [17]. A total of 906,600 SNPs were genotyped and
called using the Birdseed calling algorithm [22]. Comprehensive
QC procedures excluded SNPs that were monomorphic (55,530)
or had a call rate of less than 96% (82,462). In addition, SNPs
were excluded from the analysis on the basis of Mendelian errors
(45,778), failing the Hardy–Weinberg equilibrium test at P,
1.0*1026 (748) or minor allele frequency (MAF) ,1% (63,908).
Among the larger GOLDN population, SNPs passing QC were
used to impute untyped SNPs using MaCH software (Version
1.0.16) with HapMap Phase II (release 22, Human Genome build
36) as the reference. Further QC excluded SNPs with discrepant
alleles in comparison to mlinfo in MaCH and missing strand
information. After the imputation, we created a hybrid dataset that
included 2,543,887 SNPs, of which 584,029 were initially
genotyped in the GOLDN population. Missing genotyped data
were kept as missing in the final data set. To avoid false positive
effects from associations based on very small numbers, we limited
the current analysis to SNPs with MAF $5% for a total of
2,160,736 SNPs.
Epigenotyping
Key genes in lipid metabolism are expressed in lymphocytes
(e.g., peroxisome proliferator activated receptor a (PPARA
[23,24,25])) and CD4+ T-cells were harvested from stored
lymphocytes (collected at fasting) using antibody-linked Invitrogen
Dynabeads [26]. We lyzed cells captured on the beads and
extracted DNA using DNeasy kits (Qiagen, Venlo, Netherlands).
The Illumina Infinium Human Methylation450 Beadchip was
used to assess ,470,000 autosomal CpG sites across the genome
[27]. Our methods have been extensively described in Absher et al.
[28]. For each assay, 500 ng of DNA was treated with sodium
bisulfite (Zymo EZ DNA) prior to standard Illumina amplification,
hybridization, and imaging steps. The resulting intensity files were
analyzed with Illumina’s GenomeStudio, which generated beta
scores (proportion of total signal from the methylation specific
probe or color channel) and ‘‘detection P-values’’ (probability that
the total intensity for a given probe falls within the background
signal intensity). Beta scores with an associated detection P-value
greater than 0.01 were removed and samples with more than 1.5%
missing data points were eliminated from further analysis.
Furthermore, any CpG probes where more than 10% of samples
failed to yield adequate intensity were removed. The filtered beta
scores were then subjected to batch normalization with the
ComBat package for R software in non-parametric mode (http://
www.bu.edu/jlab/wp-assets/ComBat/Abstract.html). After quali-
ty control, we had data for 461,281 CpGs. Residual cell type
impurities may confound epigenetic association studies.[29]
Therefore, principal components based on the beta scores of all
autosomal CpGs passing QC were generated and have been
modeled in EWAS analyses to account for residual T-cell
impurities and other technical artifacts [28]. Principal components
based on the beta scores of all autosomal CpGs passing QC were
generated using the prcomp function in R (V 2.12.1).
Analysis
Change in each sterol and fatty acid concentration was
calculated as the difference between the 3.5 hour and baseline
concentrations. Statistical significance was evaluated by a test of
whether the intercept associated with change was different from
zero after adjustment for a random effect of family id using a linear
mixed model. Pearson correlation coefficients were calculated
between each sterol, fatty acid, and clinical measurements at
fasting and for change with PPL. A clusterogram of fasting and
postprandial correlation coefficients was constructed using the
heatmap.2 function in the gplots package in R [30]. Next, we
evaluated the additive effect of 2,160,736 SNPs on each fasting
sterol and fatty acid concentration using mixed models adjusted
for age, sex, center, and a random effect of family relationship.
GWAS models implemented to evaluate postprandial sterols and
fatty acids were similar but additionally adjusted for fasting
concentration. We have previously reported this population to be
very genetically homogeneous, and, therefore, we did not adjust
for population substructure [20,31]. For the epigenome-wide
analysis, each individual sterol and fatty acid was regressed on the
methylation beta score at each of the 461,281 sites adjusting for
age, sex, center, and the first 4 principal components (generated to
capture T-cell impurity) as fixed effects and a random effect of
family. We chose 4 PCs based upon the eigenvalues and scree plot
of 20 estimated PCs based on methylation data of the larger
GOLDN population. Postprandial EWAS models additionally
included adjustment for fasting sterol or fatty acid concentration.
EWAS and GWAS models were implemented in the R kinship
package (lmekin function) [32].
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GWAS and EWAS analyses generated a large number of
hypotheses requiring careful corrections for multiple testing. Given
observed correlations among the lipidomic phenotypes we used
matrix spectral decomposition [33] as a data reduction technique
to estimate the number of independent sterol phenotypes (9 of 11
were independent) and the number of independent fatty acid
phenotypes (17 of 35 were independent). Using the most
conservative approach (the Bonferroni correction) for GWAS,
alpha (a) was set to 0.05/(2,160,736*9) = 2.6*10-9 for sterols, and,
likewise, a = 0.05/(2,160,736*17) = 1.4*1029 for fatty acids. Cor-
rection for multiple testing during EWAS followed similar logic
(a = 1.2*1028 and a = 6.4*1029 for sterols and fatty acids,
respectively). SNPs and CpGs with association P-value ,
1.0*1024 were annotated using the UCSC genome browser and
ANNOVAR [34,35].
The UCSC Batch Coordinate Conversion (liftOver) module
was used to convert genome coordinates of SNPs from hg18 to
hg19 similarly as CpG sites. Any regional overlap (within 20 kb) of
EWAS and GWAS signals of at least marginal significance
(defined as P,1.0*1024) was identified. SNP association with
methylation beta score was examined (cis-meQTL association) in
regions of overlap adjusting for covariates (age, sex, center,
methylation data PCs) as fixed effects and family structure as a
random effect.
Results
Participants were on average 51.2613 years old, 55% were
male, and 60% were recruited from the GOLDN Minneapolis
field center. For a comparison of clinically measured lipids at
fasting and 3.5 hours after the intervention and other relevant
variables measured in GOLDN among the 40 participants see
Table S1. Mean concentration for each of the 11 sterols and 35
fatty acids are presented in Table 1. The average fasting values of
each metabolite were within the normal range set by TrueMass
internal standards and representative of the assay’s typical
performance. On average campesterol, b-sitosterol, desmosterol,
coprostanol, and cholestanol increased 3.5 hours after the high-fat
diet intervention and lathosterol and lanosterol decreased.
Stigmasterol, 7-dehydrocholesterol, and 7a-hydroxycholesterol
did not significantly change. Overall, total plasma fatty acids
increased postprandially (Table 1). Pairwise correlations between
fasting clinical measures, inflammatory markers, and newly
captured fatty acids and sterols are presented in Figure 1a. In
the fasting state, inflammatory markers, BMI, insulin and glucose
did not strongly correlate with clinical lipids, fatty acids, or sterols.
Fatty acids were strongly and positively correlated with each other
in addition to TG and VLDL-C. The strongest correlations
observed were among TG, VLDL-C, oleic acid and vaccenic acid.
LDL-C and total cholesterol moderately correlated with plasmal-
ogens and longer chain saturated fatty acids. Sterols, including
stigmasterol, campesterol, b-sitosterol, and cholestanol, were
strongly and positively correlated in the fasting state while
lanosterol and lathasterol were negatively correlated with those
sterols. Figure 1b shows pairwise correlations among the changes
in PPL clinical lipids, fatty acids, and sterols. Many of the observed
trends were consistent with that observed at fasting or were
stronger, particularly saturated fatty acids (palmitic acid, penta-
decanoic acid, myristic acid, and stearic acid) and their
biosynthetic products (myristoleic acid, vaccenic acid, oleic acid,
and elaidic acid) were strongly correlated with VLDL-C and TG.
In the postprandial state, change in chylomicrons positively
correlated with that group while change HDL-C negatively
correlated with that group.
Manhattan plots of association signals with P,1.0*1024 from
EWAS and GWAS of fasting sterols and fatty acids are presented
in Figure 2. GWAS results from each of 11 sterols are combined in
the upper right hand quadrant of Figure 2 and, likewise, GWAS
results for each of the 35 fatty acids are combined in the bottom
right hand quadrant. For a complete list of all CpGs and SNPs
(including annotations) shown in Figure 2, see Spreadsheet S1.
Table 2 highlights GWAS and EWAS results from analysis of
fasting sterol and fatty acids with P,1.0*1027. For sterols the
strongest genetic signal (P,4.5*1029 for each of 5 SNPs) came
from a region on chromosome 10 within the sorbin and SH3
domain containing 1 gene (SORBS1). The top two SNPs
(rs12247017 and rs12240292) met significance criteria (P,
2.6*1029) after correction for multiple testing. The second
strongest signal (P,1.8*1028 for each of 3 SNPs) was for 7a-
hydroxycholesterol in the semaphorin 6D (SEMA6D) gene on
chromosome 15. Each of the 3 SNPs lies in the first intron of an
alternate transcript of SEMA6D. Fourteen intronic SNPs in
SEMA5D on chromosome 5 were strongly associated with fasting
b-sitosterol (P#9.8*1028). A SNP (rs3918278) on chromosome 20
upstream of the matrix metallopeptidase 9 (MMP9) gene was also
associated with b-sitosterol (P = 5.6*1028). In EWAS, no CpG was
statistically significantly associated with any sterol after correction
for multiple testing. Table 2 highlights a CpG (cg02621636) on
chromosome 11 associated with coprostanol in the 39 UTR of the
membrane-spanning 4-domains, subfamily A, member 7 gene
(MS4A7). Finally, no SNP or CpG was statistically significantly
associated with any of the 35 fasting fatty acid concentrations
considered (Figure 2). Marginally significant markers are high-
lighted in Table 2 and include 2 SNPs on chromosome 5 upstream
of the protein phosphatase 2, regulatory subunit B, beta gene
(PPP2R2B) associated with di-homo-c-linoleic acid (DGLA).
Manhattan plots of association signals with P,1.0*1024 from
EWAS and GWAS of postprandial sterols and fatty acids (adjusted
for fasting concentrations) are presented in Figure 3. For a
complete list of all CpGs and SNPs (including annotations) shown
in Figure 3, see Spreadsheet S2. Table 3 highlights GWAS and
EWAS results from the postprandial analysis of sterols and fatty
acids with P,1.0*1027. No marker in EWAS or GWAS was
statistically significantly associated with any PPL sterol or fatty acid
after correction for multiple testing. Marginally significant sterol
GWAS signals included 5 markers on chromosome 14 associated
with coprostanol that were not near (within 200kb up or
downstream) any characterized gene. Four SNPs on chromosome
5 were also associated with postprandial coprostanol concentration
after adjustment for fasting concentration. The region is gene rich
and the 4 SNPs lie in intron 1 of an alternate transcript of the Kv
channel interacting protein 1 (KCNIP1) gene in addition to intron 1
of a smaller overlapping gene known as potassium large
conductance calcium-activated channel, subfamily M, beta mem-
ber 1 (KCNMB1). No CpGs were associated with any postprandial
sterol with P,1.0*1027 and, thus, are not represented in Table 3.
The SNP rs666566 in the microtubule-associated protein 6
(MAP6) gene associated with docosahexaenoic acid (DHA) was
the top hit for the fatty acid GWAS. The same SNP was also
associated with 7a-hydroxycholesterol. Another SNP (rs685448) in
MAP6 was associated with DHA with P = 1.5*1027 and with
7a-hydroxycholesterol with P = 9.5*1025. A group of SNPs
(rs16843235, rs2759275, rs16843150) upstream of ATPase, H+
transporting, lysosomal 13kDa, V1 subunit G3 (ATP6V1G3) were
associated with palmitelaidic acid. Finally, two CpGs are
highlighted in Table 3 for fatty acids, the first (cg15718583) with
DGLA in the EPH receptor B3 (EPHB3) gene and another
Genomics of PPL Phenotypes in GOLDN
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Table 1. Average concentration (nmol/gram of sample) of TrueMass panel metabolites measured at fasting and 3.5 hours after a
postprandial lipemia (PPL) challenge for 40 Genetics of Lipid Lowering Drugs and Diet Network Study participants.
TrueMass Panel Metabolites Fasting 3.5 hrs Direction* P-value
Sterols
total cholesterol 4388.866617.2 4561.126599.6 Up 0.0006
7-dehydrocholesterol 6.3262.3 6.5662.5 Up 0.2038
desmosterol 3.4561.1 3.6261.2 Up 0.0001
lanosterol 0.4260.2 0.3860.1 Down 0. 0012
lathasterol 13.9964.7 13.4765.4 Down 0.0484
cholestanol 8.9162.3 9.2162.1 Up 0.0101
coprostanol 0.0860.05 0.0960.05 Up 0.0017
b-sitosterol 11.2065.2 11.8664.7 Up ,0.0001
campesterol 6.3863.1 6.8363.0 Up ,0.0001
stigmasterol 0.4860.2 0.5160.2 Up 0.2049
7a-hydroxycholesterol 0.9460.4 0.9060.4 Down 0.2443
Fatty acid
myristic acid (14:0) 206.86688.8 934.746371.0 Up 0.0003
pentadecanoic acid (15:0) 40.97611.1 111.60635.1 Up ,0.0001
palmitic acid (16:0) 3367.236769.7 5715.2961369.6 Up ,0.0001
stearic acid (18:0) 1062.276198.1 1942.906502.7 UP ,0.0001
arachidic acid (20:0) 11.6263.21 20.7364.76 Up ,0.0001
behenic acid (22:0) 20.0367.83 21.6865.94 Up 0.0411
lignoceric acid (24:0) 17.8067.41 19.2965.68 Up 0.1372
myristoleic acid (14:1n5) 17.3369.68 101.82628.58 Up ,0.0001
palmitoleic acid (16:1n7) 318.606127.4 462.496155.0 Up ,0.0001
vaccenic acid (18:1n7) 235.01659.53 326.19668.81 Up ,0.0001
oleic acid (18:1n9) 3181.796830.1 4942.1861322.7 Up ,0.0001
eicosenoic acid (20:1n9) 22.0666.32 27.9466.91 Up ,0.0001
mead acid (20:3n9) 17.5365.7 20.2067.0 Up ,0.0001
erucic acid (22:1n9) 5.1861.13 7.1566.37 Up 0.0645
nervonic acid (24:1n9) 13.5063.49 13.6362.24 Up 0.7983
linoleic acid (18:2n6) 4574.146725.4 5254.046789.1 Up ,0.0001
c-linolenic Acid (18:3n6) 80.212624.5 91.29628.6 Up ,0.0001
eicosadienoic acid (20:2n6) 38.8769.59 49.15610.09 Up ,0.0001
di-homo-c-linolenic Acid (20:3n6) 238.18656.3 268.53658.2 Up ,0.0001
arachidonic acid (20:4n6) 1081.376216.2 1207.816236.2 Up ,0.0001
docosadienoic acid (22:2n6) 1.4160.60 1.6060.48 Up 0.2269
adrenic acid (22:4n6) 37.5368.24 45.2267.70 Up ,0.0001
docosapentaenoic acid (22:5n6) 28.7869.31 32.36610.04 Up ,0.0001
a-linolenic acid (18:3n3) 95.03632.38 136.67634.94 Up ,0.0001
stearidonic acid (18:4n3) 4.8262.18 6.1762.26 Up ,0.0001
eicsoatetraenoic acid (20:4n3) 12.0965.38 14.9864.36 Up 0.001
eicosapentaenoic acid (EPA) (20:5n3) 69.79624.61 80.86627.91 Up ,0.0001
docosapentaenoic acid (DPA) (22:5n3) 77.76619.18 94.32621.01 Up ,0.0001
docosahexaenoic acid (DHA) (22:6n3) 202.66661.02 228.33667.78 Up ,0.0001
plasmalogen (16:0) 41.6068.01 44.4769.28 Up 0.0003
plasmalogen (18:0) 33.1868.37 35.9769.41 Up 0.002
plasmalogen (18:1n7) 2.0460.97 2.1461.02 Up 0.5892
plasmalogen (18:1n9) 9.2562.51 10.3262.19 Up 0.001
palmitelaidic acid (t16:1n7) 53.03616.37 73.26623.01 Up ,0.0001
elaidic acid (t18:1n9) 216.25689.87 399.286125.89 Up ,0.0001
*direction of change in concentration of the metabolite after the PPL intervention.
doi:10.1371/journal.pone.0099509.t001
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(cg03758021) with mead acid in the PPARA interacting complex
285 (PRIC285) gene.
We explored overlap of EWAS and GWAS results within 20 kb
with P,1.0*1024 across the genome for each sterol and fatty acid
at each time point and evaluated cis-meQTL signals for
highlighted regions. Results are presented in Spreadsheet S3. Five
regions of EWAS/GWAS overlap were identified for the fasting
analysis of sterols and fatty acids including regions on chromo-
somes 1, 11, 16, 19 and 21 for fasting total cholesterol,
coprostanol, palmitoleic acid, docosapentaenoic acid, and adrenic
acid, respectively, with evidence of moderate to strong cis-meQTL
signal (5.0*1023#P#5.1*102133). Consideration of EWAS/
GWAS overlap for postprandial models highlighted 10 regions
of interest that also consist of many strong cis-meQTL signals. For
instance, cg22761176 and cg26817877, located less than 100 bp
apart on chromosome 2, were associated with a group of nearby
Figure 1. Data from 40 Genetics of Lipid Lowering Drugs and Diet Network Study participants. 1a (below the diagonal)-Pairwise
correlation of fasting sterols (bold), fatty acids (bold), clinical lipids, inflammatory markers, and other clinical measures. 1b (above the diagonal)-
Pairwise correlation of change in postprandial sterols (bold), fatty acids (bold), clinical lipids, and other clinical measures. Grey lines indicate clinical
parameters not captured postprandially.
doi:10.1371/journal.pone.0099509.g001
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SNPs with cis-meQTL association significance level ranging from
P = 0.06 to P = 2.7*10221.
Discussion
In the current study we measured the concentration of 11 sterols
and 35 fatty acids before and after a PPL challenge in 40
participants from the Genetics of Lipid Lowering Drugs and Diet
Network study. We evaluated change in plasma sterols and fatty
acids after the challenge, their correlation with other clinical
measures in the fasting and postprandial state, and integrated the
new lipid phenotypes with existing genomic data. Our findings
demonstrate marked response of sterols and fatty acids to the PPL
challenge, correlations between clinical lipids and newly measured
lipids, and provide proof-of-concept that genomic studies of sterols
and fatty acids may reveal new information about pathways
important to lipid metabolism and ultimately help identify new
biomarkers of CVD risk.
Cholesterol homeostasis, involving the balance between absorp-
tion and synthesis, influences circulating plasma lipoprotein
concentrations [36,37,38,39,40]. Therefore, several studies have
assessed whether cholesterol absorption and synthesis are also
associated with prevalent CVD [40]. Results have varied with
some studies reporting that higher cholesterol absorption and/or
lower cholesterol synthesis is associated with increased
[41,42,43,44,45,46,47], decreased [48,49], or no difference in
CVD risk [50,51,52]. Because cholesterol absorption and biosyn-
thesis are difficult to measure directly, we measured circulating
concentrations of several cholesterol-related sterols as biomarkers
of these processes. b-Sitosterol, campesterol, and stigmasterol are
plant sterols (phytosterols) similar in structure to cholesterol.
Although the absolute amount of phytosterols absorbed in the gut
is very low, their plasma concentrations are correlated with
cholesterol absorption [53]. Cholestanol, an endogenous 5-a–
reduced metabolite of cholesterol, is also correlated with choles-
terol absorption [53,54]. Lanosterol, lathosterol, 7-dehydrocholes-
terol, and desmosterol, are endogenous precursors of cholesterol
correlated with cholesterol synthesis [54,55]. Other metabolic
products measured in this study include an oxidized derivative of
cholesterol, 7a-hydroxylcholesterol, and coprostanol, a dietary
cholesterol derivative produced by the intestinal microbiota
[56,57,58,59]. Overall, markers of cholesterol absorption signifi-
cantly increased and markers of cholesterol synthesis decreased
3.5 hours after the high fat meal. Ultimately, a better understand-
ing of the genetic background of these processes can help explain
mechanisms related to postprandial lipemia and even inform
future studies relating sterols to CVD risk.
Fatty acid metabolism is also intricately tied to CVD health.
Increasing dietary saturated fatty acid intake increases total
cholesterol, LDL-C and TG [60,61,62,63]. Subsequently, reduced
saturated fatty acid intake has been an important dietary
recommendation for the reduction of CVD risk [64]. However,
individual saturated fatty acids have unique properties, form a
variety of metabolites and, thus, have diverse biological functions
[65]. Importantly, not all saturated fatty acids have the same
cholesterol-raising effects. For instance, stearic acid has a neutral
effect on total cholesterol, LDL-C, and HDL-C, whereas lauric,
myristic, and palmitic acids increase total cholesterol, LDL-C, and
HDL-C, with myristic acid having the most potent hypercholes-
terolemic effect [60,66,67]. Due to the complexity of saturated
fatty acids in foods, their consumption in the context of other
nutrients and sources of error in dietary exposure information, the
effect of individual saturated fatty acids on CVD endpoints has
varied in the literature [65,68,69,70,71]. An advantage of the
study set within GOLDN is that the meal has been standardized
and each participant acted as his or her own control. We evaluated
saturated fatty acids (myristic acid, pentadecanoic acid, palmitic
acid, stearic acid, arachidic acid, behenic acid, and lignoceric acid)
and their direct biosynthetic products (myristoleic acid, palmitoleic
acid, vaccenic acid, oleic acid, eicosenoic acid, mead acid, erucic
acid, and nervonic acid), but also essential fatty acids (a-linolenic
acid, linoleic acid) and their longer, more desaturated derivatives
(g-linolenic acid, eicosadienoic acid, di-homo-g-linolenic acid,
arachidonic acid, docosadienoic acid, adrenic acid, docosapentae-
noic acid, stearidonic acid, eicosoatetraenoic acid, eicosapentae-
noic acid, docosapentaenoic acid, and docosahexaenoic acid), 4
plasmalogens and the trans fatty acids elaidic acid and
palmitelaidic acids. In our small study, fatty acids present in
bovine milk fat [72] (saturated fatty acids- palmitic acid, myristic
acid, and stearic acid; mono-unsaturated fatty acid- oleic acid; and
trans fatty acids vaccenic acid and elaidic acid) correlated most
closely with TG and lipid species that carry TG in response to the
PPL challenge. Yet several other fatty acid species (many
derivatives of these saturated fatty acids) positively correlated with
this group potentially reflecting intrinsic metabolic response to the
fat load (e.g. palmitoleic acid, plamitelaidic acid, eicosenoic acid,
erucic acid). Importantly, our findings support prior research
correlating fatty acids with clinical lipids and provide a unique
setting to evaluate the genomic determinants of inter-individual
differences in specific fatty acids after a standardized PPL
challenge.
Figure 2. Manhattan plots for markers with P,0.0001 from epigenome-wide association study and genome-wide association study.
Phenotypes include 11 sterols and 35 fatty acids measured at fasting.
doi:10.1371/journal.pone.0099509.g002
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GWAS and EWAS of fasting sterol and fatty acid concentra-
tions highlighted several regions of interest with biologically
plausible association. A cluster of SNPs on chromosome 10
associated with b-sitosterol is located in SORBS1, which encodes a
protein in the insulin signaling pathway [73]. Insulin resistance has
been linked to high cholesterol synthesis and decreased cholesterol
absorption in prior reports [54,74,75]. Further studies are needed
to determine if variation in SORBS1 may help explain such
observations. SNPs in SEMA6D and SEMA5A were highlighted
as being associated with fasting 7a-hydroxycholesterol and
b-sitosterol, respectively. Semaphorins have important regulatory
functions in the cardiac, circulatory and immune systems
[76,77,78,79,80]. For instance, SEMA6D has been linked to
T-cell activation [81] and SEMA5A promotes angiogenesis
through increased endothelial cell proliferation, migration, and
downregulated apoptosis [82]. SEMA5A action may be facilitated
by MMP9, another gene reported as being associated with b-
sitosterol in Table 2 [82]. MMP9 has been indicated in vascular
injury, inflammation, and tissue remodeling associated with CVD
[83,84,85,86]. A CpG in the 39UTR of MS4A7 was associated
Table 2. Top genome-wide association study (GWAS) and epigenome-wide association study (EWAS) results for fasting sterols and
fatty acids.
Marker Chr Location Lipid Gene Gene Proximity P-value
Sterol GWAS
rs12247017 10 97270729 b-sitosterol SORBS1 intronic 4.9*10210
rs12240292 10 97273066 b-sitosterol SORBS1 intronic 4.5*10210
rs12772243 10 97295589 b-sitosterol SORBS1 intronic 4.5*1029
rs12776555 10 97284362 b-sitosterol SORBS1 intronic 4.5*1029
rs4918944 10 97283881 b-sitosterol SORBS1 intronic 4.5*1029
rs281282 15 47679257 7a-hydroxycholesterol SEMA6D intronic 1.8*1028
rs281284 15 47680407 7a-hydroxycholesterol SEMA6D intronic 1.8*1028
rs281294 15 47683646 7a-hydroxycholesterol SEMA6D intronic 1.8*1028
rs1631842 1 232447391 campesterol SIPA1L2 ,100kb upstream 3.1*1028
rs1766581 1 232447293 campesterol SIPA1L2 ,100kb upstream 3.1*1028
rs10059341 5 9325205 b-sitosterol SEMA5A intronic 3.9*1028
rs10065505 5 9301719 b-sitosterol SEMA5A intronic 3.9*1028
rs13360783 5 9299238 b-sitosterol SEMA5A intronic 3.9*1028
rs1557879 5 9308539 b-sitosterol SEMA5A intronic 3.9*1028
rs3777306 5 9295681 b-sitosterol SEMA5A intronic 3.9*1028
rs3777311 5 9301324 b-sitosterol SEMA5A intronic 3.9*1028
rs3777312 5 9301496 b-sitosterol SEMA5A intronic 3.9*1028
rs3777316 5 9302667 b-sitosterol SEMA5A intronic 3.9*1028
rs3777320 5 9307427 b-sitosterol SEMA5A intronic 3.9*1028
rs3777325 5 9319778 b-sitosterol SEMA5A intronic 3.9*1028
rs3777327 5 9323467 b-sitosterol SEMA5A intronic 3.9*1028
rs3797980 5 9328316 b-sitosterol SEMA5A intronic 3.9*1028
rs17196572 5 9298117 b-sitosterol SEMA5A intronic 4.7*1028
rs3918278 20 44635654 b-sitosterol MMP9 ,2k bupstream 5.6*1028
rs11070582 15 47686590 7a-hydroxycholesterol SEMA6D intronic 6.5*1028
rs3822789 5 9322477 b-sitosterol SEMA5A intronic 9.8*1028
rs697651 2 155323278 7-dehydrocholesterol GALNT13 downstream 1.2*1027
Sterol EWAS
cg02621636 11 60161999 coprostanol MS4A7 in 3’utr 8.3*1028
FA GWAS
rs6895471 5 146472853 di-homo-c-linoleic PPP2R2B ,10kb upstream 6.3*1028
rs17105882 5 146465362 di-homo-c-linoleic PPP2R2B ,10kb upstream 6.3*1028
rs6795707 3 195937410 plasmalogen (16:0) ZDHHC19 intronic 8.0*1028
rs1859124 7 86747876 eicsoatetraenoic DMTF1 ,50 kb upstream 9.2*1028
rs8118851 20 56292879 stearic PMEPA1 ,10 kb upstream 1.0*1027
FA EWAS
cg23221506 17 73175571 plasmalogen (18:0) SUMO2 intron 1.8*1028
Chr, chromosome; FA, fatty acid.
doi:10.1371/journal.pone.0099509.t002
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Figure 3. Manhattan plots for markers with P, 0.0001 from epigenome-wide association study and genome-wide association
study. Phenotypes include 11 postprandial sterols and 35 postprandial fatty acids after adjustment for fasting concentration.
doi:10.1371/journal.pone.0099509.g003
Table 3. Top genome-wide association study (GWAS) and epigenome-wide association study (EWAS) results for postprandial
sterols and fatty acids.
Marker Chr Location Lipid Gene Gene Proximity P-value
Sterol GWAS
rs17490390 5 152362706 7a-hydroxycholesterol AK123816 ,10 kb downstream 1.0*1028
rs666566 11 75302420 7a-hydroxycholesterol MAP6 intronic 2.4*1028
rs1627411 14 43171328 coprostanol - - 2.7*1028
rs1698533 14 43172278 coprostanol - - 2.8*1028
rs1698534 14 43172343 coprostanol - - 2.8*1028
rs1712738 14 43163097 coprostanol - - 3.0*1028
rs1627270 14 43168725 coprostanol - - 3.6*1028
rs7203768 16 73301302 cholestanol ZFHX3 ,200 kb downstream 5.4*1028
rs12826237 12 76073557 stigmasterol GLIPR1 ,100 kb downstream 7.0*1028
rs314112 5 169813739 coprostanol KCNMB1 intronic 7.8*1028
rs314111 5 169813844 coprostanol KCNMB1 intronic 8.1*1028
rs314113 5 169813296 coprostanol KCNMB1 intronic 8.1*1028
rs314109 5 169814432 coprostanol KCNMB1 intronic 8.2*1028
rs17223072 12 76080856 stigmasterol GLIPR1 ,100kb downstream 1.1*1027
FA GWAS
rs666566 11 75302420 docosahexaenoic MAP6 intronic 4.1*1029
rs757079 17 31325103 arachidonic SPACA3 ,0.2kb downstream 4.9*1029
rs28958 17 31324657 arachidonic SPACA3 intronic 5.3*1029
rs13285452 9 83595061 docosadienoic - - 3.9*1028
rs7025679 9 83513137 docosadienoic - - 4.1*1028
rs7350230 9 83572513 docosadienoic - - 4.5*1028
rs7024926 9 83576272 docosadienoic - - 5.5*1028
rs16843235 1 198485694 palmitelaidic ATP6V1G3 ,10 kb upstream 6.5*1028
rs9503012 6 1707004 behenic GMDS intronic 1.0 *1027
rs1628439 12 95400638 docosapentaenoic NDUFA12 ,5 kb downstream 1.0 *1027
FA EWAS
cg15718583 3 184231385 di-homo-c-linoleic EPHB3 ,50 kb upstream 2.1 *1028
cg03758021 20 62208140 mead PRIC285 ,5 kb downstream 6.3 *1028
Chr, chromosome; FA, fatty acid.
doi:10.1371/journal.pone.0099509.t003
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with coprostanol. MS4A7 encodes a member of the membrane-
spanning 4A gene family, localized to chromosome 11q12, in a
cluster of other family members. MS4A7 is expressed in
lymphocytes and is likely involved in signal transduction [87]
SNPs upstream of PPP2R2B were associated with DGLA, an n-6
polyunsaturated fatty acid (PUFA). PPP2R2B encodes a brain
specific regulatory subunit of a protein phosphatase that is not
easily relatable to CVD and lipid metabolism. However, a recent
report that fine-mapped a large region on chromosome 5q31-33
for early onset coronary artery disease (CAD) across two large
family studies identified PPP2R2B as one of four genes that showed
consistent and strong association with both LDL-C and CAD [88].
After adjusting for fasting concentration, GWAS and EWAS of
individual PPL sterol and fatty acid concentrations also yielded
unique results in or near genes with compelling biological
significance to lipid metabolism and CVD. ZFHX3 is a transcrip-
tion factor with cardiac and immune cell expression. Though our
signal for cholestanol is much farther downstream, SNPs in
ZFHX3 have been linked to stroke and atrial fibrillation in prior
GWAS [89,90,91]. GLI pathogenesis-related 1 (GLIPR1) may be
linked immune cell function as the gene is highly expressed in
multiple immune cell types [92]. Calcium activated K+ channels
(KCa) have an essential role in arterial function regulating vascular
tone [93]. Our study highlights SNPs in KCNMB1 (encoding a
KCa subunit) which were associated with postprandial coprosta-
nol. Previous research has linked mutations in KCNMB1 to
hypertension, myocardial infarction and stroke [94]. Additionally,
increased expression of vascular KCa channels have been
demonstrated in coronary vessels from patients with CAD [95].
GDP-mannose-4,6-dehydratase (GMDS), highlighted for associa-
tion with behenic acid, is regulator of post-translational modifi-
cation processes important for cell surface lipids and proteins [96].
Other genes annotated in GWAS are more difficult to link to
postprandial lipid metabolism. For instance, MAP6 is involved in
microtubule stabilization in many cell types, and sperm acrosome
associated 3 (SPACA3) is a sperm surface membrane protein
[92,97,98]. Finally, fatty acid EWAS results highlight a marker
(cg03758021) closely downstream of PRIC285, a nuclear co-
activator of the transcription factor PPARA which is intricately
involved inflammation and lipid metabolism in the liver [99,100].
In addition to evaluating the most significant EWAS and
GWAS results in this study we mined all results presented in
Spreadsheets S1 and S2 for postprandial lipemia and cardiovas-
cular risk loci published in the literature [2,10,11,101]. A SNP
(rs219562) near APOB was associated with postprandial stigmas-
terol (P = 6.0*1025) and a CpG (cg20691580) in APOC3 was
associated with postprandial palmitelaidic acid (P = 3.0*1025).
APOB and APOC3 have been associated with postprandial clinical
lipids [2]. Additionally, CpGs in WDR12 and SH2B3, respectively,
were found in Spreadsheet S1 among the fasting fatty acid EWAS
results. Finally, a SNP (rs11239204) near CXCL12 was associated
(P = 1.8*1025) with postprandial plasmalogen 18:1n9 concentra-
tion. WDR12, SH2B3 and CXCL12 were among 13 loci
highlighted in a large GWAS of CAD [101]. Though none of
these findings meet criteria for statistical significance after
correction for multiple testing, they support the potential
usefulness of lipidomic studies in unraveling biological mechanisms
by which genes relate to more complex CVD phenotypes.
We also explored the potential to integrate EWAS and GWAS
results from these analyses. Taking a regionalized approach our
results demonstrate several examples of within phenotype EWAS/
GWAS overlap in both fasting and postprandial models. In the
future, we hope to have data from a larger sample in GOLDN that
will enable us to model SNPs and CpG sites (fitting criteria as cis-
meQTLs) jointly on a phenotype to better deduce interplay among
markers. While our small sample restricted the pursuit of these
additional analyses, our data demonstrate the potential for
functional crosstalk between genomic layers supporting further
expansion of this research set within GOLDN.
We note several limitations to our study. Most importantly, our
sample size was small for the high dimensional data analyses
pursued. Therefore, it was difficult to identify markers meeting the
strict criteria necessary to achieve statistical significance in the
context of this study. Consequently, some false positive and
alternatively, false negative findings may have occurred. Replica-
tion in a larger group from GOLDN and external cohorts is
needed. Still, we present novel research that highlights the
potential of integrating ‘omic’ data to make progress in the field
of translational research and personalized medicine in the context
of an altered postprandial lipid response.
To our knowledge, this is the first study evaluating the lipid
response to a PPL challenge with fine resolution of phenotypes via
lipidomic assays. Additionally, a new dimension to the study of
postprandial lipemia was explored by integrating GWAS and
EWAS data with the lipidomic measurements. Our study
highlighted several novel genes involved in lipid metabolism,
endothelial function, immune function and cell signaling. Overall,
the results demonstrate that small molecule lipids correlate with
clinical lipids, respond to the PPL intervention, and that genomic
markers might help unravel mechanisms related to lipid metab-
olism in the fasting and non-fasting state. This report sets the
groundwork to expand this research in GOLDN and other cohorts
to help translate novel biomarkers of the postprandial lipid
response to use in the diagnosis, prevention and treatment of
dyslipidemias and CVD.
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